1-8 of 8
Rainer Boxhammer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)

Jung Hyun Her, Dominik Pretscher, Sungyoo Cho, Yu-Kyeong Hwang, Timm Hoeres, Rainer Boxhammer, Stefan Steidl, Maria Patra, Juergen Schanzer, Jan Endell
Journal: Blood
Blood (2019) 134 (Supplement_1): 3801.
https://doi.org/10.1182/blood-2019-128511
Published: 2019
Journal Articles

Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide

Dimitrios Mougiakakos, MD, Simon Voelkl, PhD, Christian Bach, Andrej Stoll, Katrin Bitterer, Fabian Beier, MD, Jan Endell, Rainer Boxhammer, Jörg Thomas Bittenbring, MD, Andreas Mackensen, MD, Heiko Bruns, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4064.
https://doi.org/10.1182/blood-2019-124886
Published: 2019
Journal Articles

Expression of CD19 Antigen on Chronic Lymphocytic Leukemia Cells after Tafasitamab (Anti-CD19) Treatment: Phase I Trial Data

Rainer Boxhammer, Frank Striebel, Roland Baumgartner, Jan Endell
Journal: Blood
Blood (2019) 134 (Supplement_1): 5061.
https://doi.org/10.1182/blood-2019-128613
Published: 2019
Journal Articles

Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies

Pedro Horna, MD, Grzegorz Nowakowski, MD, Jan Endell, Rainer Boxhammer
Journal: Blood
Blood (2019) 134 (Supplement_1): 5345.
https://doi.org/10.1182/blood-2019-129600
Published: 2019
Journal Articles

A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Marc S. Raab, MD, Manik Chatterjee, MD, Hartmut Goldschmidt, MD, Hermine Agis, MD, Igor Blau, Hermann Einsele, MD, Monika Engelhardt, MD PhD, Barbara Ferstl, MD, Martin Gramatzki, MD, Christoph Röllig, MD, Katja Weisel, MD, Tiantom Jarutat, MD, Dominika Weinelt, MD, Jan Endell, PhD, Rainer Boxhammer, PhD, Christian Peschel, MD
Journal: Blood
Blood (2016) 128 (22): 1152.
https://doi.org/10.1182/blood.V128.22.1152.1152
Published: 2016
Journal Articles

MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal Activity In Vivo and Shows Synergistic Efficacy in Combination with Different Antineoplastic Compounds

Rainer Boxhammer, Johannes Weirather, PhD, Stefan Steidl, PhD, Jan Endell, PhD
Journal: Blood
Blood (2015) 126 (23): 3015.
https://doi.org/10.1182/blood.V126.23.3015.3015
Published: 2015
Journal Articles

Synergistic in Vitro Activity of MOR202, a Human CD38 Antibody, in Combination with Pomalidomide

Jan Endell, Rainer Boxhammer, Stefan Steidl
Journal: Blood
Blood (2014) 124 (21): 5712.
https://doi.org/10.1182/blood.V124.21.5712.5712
Published: 2014
Journal Articles

The Activity of MOR202, a Fully Human Anti-CD38 Antibody, Is Complemented by ADCP and Is Synergistically Enhanced by Lenalidomide in Vitro and in Vivo

Jan Endell, Rainer Boxhammer, Cornelia Wurzenberger, Daniel Ness, Stefan Steidl
Journal: Blood
Blood (2012) 120 (21): 4018.
https://doi.org/10.1182/blood.V120.21.4018.4018
Published: 2012